Drug Interactions With Risk of QT-prolongation in a General Hospital

QT-prolongation Clinical Trial

Official title: Drug Interactions With Risk of QT-prolongation in a General Hospital: an Epidemiological Point Prevalence Study

Status Completed

Clinical Trial Summary

In this epidemiological point prevalence study, medication profiles of patients with haloperidol treatment will be checked for drug interactions with risk of QT-prolongation. Additional clinical risk factors for developing QT-prolongation and safety measurements will be documented.

Clinical Trial Description

Study design: epidemiological point prevalence study

Target population: Patients with haloperidol treatment

The following aspects will be investigated:

• The medication profiles will be checked for drug interactions with risk of QT-prolongation.

• Clinical risk factors for developing QT-prolongation (gender, age, (history of) cardiovascular disease, comorbidity,...) and lab results will be collected.

• Safety measurements (e.g. ECG) will be documented. ;

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Long QT Syndrome
• QT-prolongation

• NCT number: NCT02043912
• Study type: Observational
• Source: Katholieke Universiteit Leuven
• Status: Completed
• Phase: N/A
• Start date: July 2013
• Completion date: April 2014